Does the media prefer AKBA or GERN?

In the previous week, Geron had 5 more articles in the media than Akebia Therapeutics. MarketBeat recorded 8 mentions for Geron and 3 mentions for Akebia Therapeutics. Geron's average media sentiment score of 0.74 beat Akebia Therapeutics' score of 0.68 indicating that Geron is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Akebia Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Geron 3 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor DSGN or AKBA?

In the previous week, Design Therapeutics had 1 more articles in the media than Akebia Therapeutics. MarketBeat recorded 4 mentions for Design Therapeutics and 3 mentions for Akebia Therapeutics. Design Therapeutics' average media sentiment score of 0.85 beat Akebia Therapeutics' score of 0.68 indicating that Design Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Design Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Akebia Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ANNX or AKBA?

In the previous week, Annexon had 4 more articles in the media than Akebia Therapeutics. MarketBeat recorded 7 mentions for Annexon and 3 mentions for Akebia Therapeutics. Annexon's average media sentiment score of 0.78 beat Akebia Therapeutics' score of 0.68 indicating that Annexon is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Annexon 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Akebia Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer OLMA or AKBA?

In the previous week, Olema Pharmaceuticals had 2 more articles in the media than Akebia Therapeutics. MarketBeat recorded 5 mentions for Olema Pharmaceuticals and 3 mentions for Akebia Therapeutics. Olema Pharmaceuticals' average media sentiment score of 0.73 beat Akebia Therapeutics' score of 0.68 indicating that Olema Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Olema Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Akebia Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, AKBA or ANL?

Akebia Therapeutics has higher revenue and earnings than Adlai Nortye. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Akebia Therapeutics $236.20M 1.14 -$5.34M -$0.11 N/A Adlai Nortye $18.06M 53.53 -$35.53M N/A N/A

Does the media refer more to AKBA or ANL?

In the previous week, Akebia Therapeutics and Akebia Therapeutics both had 3 articles in the media. Adlai Nortye's average media sentiment score of 0.80 beat Akebia Therapeutics' score of 0.68 indicating that Adlai Nortye is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Akebia Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Adlai Nortye 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Akebia Therapeutics (AKBA) Competitors

$0.97 -0.01 (-0.87%)

As of 09/4/2026 04:00 PM Eastern

Compare

AKBA vs. GERN, DSGN, ANNX, OLMA, and ANL

Should you buy Akebia Therapeutics stock or one of its competitors? Akebia Therapeutics's main competitors and comparable companies include Geron (GERN), Design Therapeutics (DSGN), Annexon (ANNX), Olema Pharmaceuticals (OLMA), and Adlai Nortye (ANL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Akebia Therapeutics compare to Geron?

Akebia Therapeutics (NASDAQ:AKBA) and Geron (NASDAQ:GERN) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, valuation, risk, media sentiment and analyst recommendations.

In the previous week, Geron had 5 more articles in the media than Akebia Therapeutics. MarketBeat recorded 8 mentions for Geron and 3 mentions for Akebia Therapeutics. Geron's average media sentiment score of 0.74 beat Akebia Therapeutics' score of 0.68 indicating that Geron is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Akebia Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Geron	3 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Akebia Therapeutics has higher revenue and earnings than Geron. Geron is trading at a lower price-to-earnings ratio than Akebia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akebia Therapeutics	$236.20M	1.14	-$5.34M	-$0.11	N/A
Geron	$183.88M	5.49	-$83.50M	-$0.11	N/A

Akebia Therapeutics presently has a consensus price target of $3.75, suggesting a potential upside of 284.73%. Geron has a consensus price target of $4.00, suggesting a potential upside of 154.78%. Given Akebia Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Akebia Therapeutics is more favorable than Geron.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Akebia Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Geron	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

33.9% of Akebia Therapeutics shares are held by institutional investors. Comparatively, 73.7% of Geron shares are held by institutional investors. 4.3% of Akebia Therapeutics shares are held by insiders. Comparatively, 1.7% of Geron shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Akebia Therapeutics has a net margin of -13.54% compared to Geron's net margin of -34.17%. Geron's return on equity of -24.48% beat Akebia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Akebia Therapeutics	-13.54%	-88.88%	-7.74%
Geron	-34.17%	-24.48%	-10.30%

Akebia Therapeutics has a beta of 0.19, indicating that its share price is 81% less volatile than the broader market. Comparatively, Geron has a beta of 0.61, indicating that its share price is 39% less volatile than the broader market.

Summary

Akebia Therapeutics beats Geron on 9 of the 15 factors compared between the two stocks.

How does Akebia Therapeutics compare to Design Therapeutics?

Design Therapeutics (NASDAQ:DSGN) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends, media sentiment and valuation.

Design Therapeutics has a beta of 1.66, indicating that its stock price is 66% more volatile than the broader market. Comparatively, Akebia Therapeutics has a beta of 0.19, indicating that its stock price is 81% less volatile than the broader market.

Design Therapeutics has a net margin of 0.00% compared to Akebia Therapeutics' net margin of -13.54%. Design Therapeutics' return on equity of -34.03% beat Akebia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Design Therapeutics	N/A	-34.03%	-32.05%
Akebia Therapeutics	-13.54%	-88.88%	-7.74%

56.6% of Design Therapeutics shares are held by institutional investors. Comparatively, 33.9% of Akebia Therapeutics shares are held by institutional investors. 17.1% of Design Therapeutics shares are held by insiders. Comparatively, 4.3% of Akebia Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Design Therapeutics had 1 more articles in the media than Akebia Therapeutics. MarketBeat recorded 4 mentions for Design Therapeutics and 3 mentions for Akebia Therapeutics. Design Therapeutics' average media sentiment score of 0.85 beat Akebia Therapeutics' score of 0.68 indicating that Design Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Design Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Akebia Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Akebia Therapeutics has higher revenue and earnings than Design Therapeutics. Design Therapeutics is trading at a lower price-to-earnings ratio than Akebia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Design Therapeutics	N/A	N/A	-$69.79M	-$1.18	N/A
Akebia Therapeutics	$236.20M	1.14	-$5.34M	-$0.11	N/A

Design Therapeutics presently has a consensus target price of $16.50, indicating a potential upside of 8.98%. Akebia Therapeutics has a consensus target price of $3.75, indicating a potential upside of 284.73%. Given Akebia Therapeutics' higher possible upside, analysts clearly believe Akebia Therapeutics is more favorable than Design Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Akebia Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Design Therapeutics beats Akebia Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Akebia Therapeutics compare to Annexon?

Annexon (NASDAQ:ANNX) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, media sentiment, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.

Akebia Therapeutics has higher revenue and earnings than Annexon. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annexon	N/A	N/A	-$206.69M	-$1.16	N/A
Akebia Therapeutics	$236.20M	1.14	-$5.34M	-$0.11	N/A

Annexon has a beta of 1.21, suggesting that its share price is 21% more volatile than the broader market. Comparatively, Akebia Therapeutics has a beta of 0.19, suggesting that its share price is 81% less volatile than the broader market.

Annexon has a net margin of 0.00% compared to Akebia Therapeutics' net margin of -13.54%. Akebia Therapeutics' return on equity of -88.88% beat Annexon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annexon	N/A	-106.15%	-79.82%
Akebia Therapeutics	-13.54%	-88.88%	-7.74%

In the previous week, Annexon had 4 more articles in the media than Akebia Therapeutics. MarketBeat recorded 7 mentions for Annexon and 3 mentions for Akebia Therapeutics. Annexon's average media sentiment score of 0.78 beat Akebia Therapeutics' score of 0.68 indicating that Annexon is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Annexon	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Akebia Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Annexon presently has a consensus target price of $15.14, indicating a potential upside of 210.94%. Akebia Therapeutics has a consensus target price of $3.75, indicating a potential upside of 284.73%. Given Akebia Therapeutics' higher possible upside, analysts clearly believe Akebia Therapeutics is more favorable than Annexon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annexon	2 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40
Akebia Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

33.9% of Akebia Therapeutics shares are owned by institutional investors. 10.3% of Annexon shares are owned by company insiders. Comparatively, 4.3% of Akebia Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Annexon beats Akebia Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Akebia Therapeutics compare to Olema Pharmaceuticals?

Olema Pharmaceuticals (NASDAQ:OLMA) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, institutional ownership, valuation, earnings, risk, profitability and dividends.

Akebia Therapeutics has higher revenue and earnings than Olema Pharmaceuticals. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.12	N/A
Akebia Therapeutics	$236.20M	1.14	-$5.34M	-$0.11	N/A

Olema Pharmaceuticals currently has a consensus price target of $42.40, indicating a potential upside of 294.42%. Akebia Therapeutics has a consensus price target of $3.75, indicating a potential upside of 284.73%. Given Olema Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Olema Pharmaceuticals is more favorable than Akebia Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Olema Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Akebia Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Olema Pharmaceuticals has a beta of 1.98, indicating that its share price is 98% more volatile than the broader market. Comparatively, Akebia Therapeutics has a beta of 0.19, indicating that its share price is 81% less volatile than the broader market.

In the previous week, Olema Pharmaceuticals had 2 more articles in the media than Akebia Therapeutics. MarketBeat recorded 5 mentions for Olema Pharmaceuticals and 3 mentions for Akebia Therapeutics. Olema Pharmaceuticals' average media sentiment score of 0.73 beat Akebia Therapeutics' score of 0.68 indicating that Olema Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Olema Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Akebia Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Olema Pharmaceuticals has a net margin of 0.00% compared to Akebia Therapeutics' net margin of -13.54%. Olema Pharmaceuticals' return on equity of -48.26% beat Akebia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Olema Pharmaceuticals	N/A	-48.26%	-43.04%
Akebia Therapeutics	-13.54%	-88.88%	-7.74%

91.8% of Olema Pharmaceuticals shares are owned by institutional investors. Comparatively, 33.9% of Akebia Therapeutics shares are owned by institutional investors. 12.6% of Olema Pharmaceuticals shares are owned by insiders. Comparatively, 4.3% of Akebia Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Olema Pharmaceuticals beats Akebia Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Akebia Therapeutics compare to Adlai Nortye?

Akebia Therapeutics (NASDAQ:AKBA) and Adlai Nortye (NASDAQ:ANL) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk.

Akebia Therapeutics has higher revenue and earnings than Adlai Nortye.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akebia Therapeutics	$236.20M	1.14	-$5.34M	-$0.11	N/A
Adlai Nortye	$18.06M	53.53	-$35.53M	N/A	N/A

In the previous week, Akebia Therapeutics and Akebia Therapeutics both had 3 articles in the media. Adlai Nortye's average media sentiment score of 0.80 beat Akebia Therapeutics' score of 0.68 indicating that Adlai Nortye is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Akebia Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Adlai Nortye	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Adlai Nortye has a net margin of 0.00% compared to Akebia Therapeutics' net margin of -13.54%. Adlai Nortye's return on equity of 0.00% beat Akebia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Akebia Therapeutics	-13.54%	-88.88%	-7.74%
Adlai Nortye	N/A	N/A	N/A

Akebia Therapeutics currently has a consensus target price of $3.75, suggesting a potential upside of 284.73%. Adlai Nortye has a consensus target price of $24.25, suggesting a potential upside of 61.56%. Given Akebia Therapeutics' higher probable upside, research analysts plainly believe Akebia Therapeutics is more favorable than Adlai Nortye.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Akebia Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Adlai Nortye	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

33.9% of Akebia Therapeutics shares are held by institutional investors. Comparatively, 35.2% of Adlai Nortye shares are held by institutional investors. 4.3% of Akebia Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Akebia Therapeutics has a beta of 0.19, indicating that its share price is 81% less volatile than the broader market. Comparatively, Adlai Nortye has a beta of 1.04, indicating that its share price is 4% more volatile than the broader market.

Summary

Adlai Nortye beats Akebia Therapeutics on 9 of the 13 factors compared between the two stocks.

Get Akebia Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AKBA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AKBA vs. The Competition

Export

Metric	Akebia Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$272.48M	$4.02B	$7.27B	$12.91B
Dividend Yield	N/A	3.60%	2.53%	8.90%
P/E Ratio	-8.86	12.65	272.43	25.42
Price / Sales	1.14	1,243.68	594.02	75.77
Price / Cash	N/A	107.40	77.39	52.28
Price / Book	10.83	16.15	12.85	6.17
Net Income	-$5.34M	-$22.76M	$3.48B	$349.50M
7 Day Performance	10.94%	0.30%	0.99%	-0.15%
1 Month Performance	-24.44%	8.24%	5.49%	1.02%
1 Year Performance	-67.07%	49.08%	24.34%	14.50%

Akebia Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AKBA Akebia Therapeutics	2.3606 of 5 stars	$0.97 -0.9%	$3.75 +284.7%	-67.7%	$272.48M	$236.20M	N/A	430
GERN Geron	1.9121 of 5 stars	$1.49 -1.3%	$4.00 +168.5%	+13.8%	$970.14M	$183.88M	N/A	70
DSGN Design Therapeutics	1.1525 of 5 stars	$15.09 -0.1%	$16.50 +9.3%	+147.8%	$945.61M	N/A	N/A	40	Positive News
ANNX Annexon	2.0926 of 5 stars	$4.94 -0.6%	$15.33 +210.4%	+126.5%	$942.21M	N/A	N/A	60	Positive News Analyst Forecast
OLMA Olema Pharmaceuticals	2.2316 of 5 stars	$10.43 +1.6%	$42.40 +306.5%	+69.3%	$898.60M	N/A	N/A	70

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AKBA) was last updated on 9/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Akebia Therapeutics (AKBA) Competitors

AKBA vs. GERN, DSGN, ANNX, OLMA, and ANL

How does Akebia Therapeutics compare to Geron?

Summary

How does Akebia Therapeutics compare to Design Therapeutics?

Summary

How does Akebia Therapeutics compare to Annexon?

Summary

How does Akebia Therapeutics compare to Olema Pharmaceuticals?

Summary

How does Akebia Therapeutics compare to Adlai Nortye?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKBA vs. The Competition

Akebia Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Akebia Therapeutics (AKBA) Competitors

AKBA vs. GERN, DSGN, ANNX, OLMA, and ANL

How does Akebia Therapeutics compare to Geron?

Does the media prefer AKBA or GERN?

Which has higher earnings & valuation, AKBA or GERN?

Do analysts rate AKBA or GERN?

Do institutionals & insiders hold more shares of AKBA or GERN?

Is AKBA or GERN more profitable?

Which has more risk & volatility, AKBA or GERN?

Summary

How does Akebia Therapeutics compare to Design Therapeutics?

Which has more risk and volatility, DSGN or AKBA?

Is DSGN or AKBA more profitable?

Do insiders and institutionals believe in DSGN or AKBA?

Does the media favor DSGN or AKBA?

Which has preferable valuation and earnings, DSGN or AKBA?

Do analysts rate DSGN or AKBA?

Summary

How does Akebia Therapeutics compare to Annexon?

Which has better earnings & valuation, ANNX or AKBA?

Which has more risk and volatility, ANNX or AKBA?

Is ANNX or AKBA more profitable?

Does the media favor ANNX or AKBA?

Do analysts rate ANNX or AKBA?

Do institutionals and insiders hold more shares of ANNX or AKBA?

Summary

How does Akebia Therapeutics compare to Olema Pharmaceuticals?

Which has stronger valuation and earnings, OLMA or AKBA?

Do analysts recommend OLMA or AKBA?

Which has more volatility & risk, OLMA or AKBA?

Does the media prefer OLMA or AKBA?

Is OLMA or AKBA more profitable?

Do institutionals and insiders believe in OLMA or AKBA?

Summary

How does Akebia Therapeutics compare to Adlai Nortye?

Which has preferable valuation and earnings, AKBA or ANL?

Does the media refer more to AKBA or ANL?

Is AKBA or ANL more profitable?

Do analysts rate AKBA or ANL?

Do insiders & institutionals have more ownership in AKBA or ANL?

Which has more volatility & risk, AKBA or ANL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKBA vs. The Competition

Akebia Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools